CDC admits death toll is inflated! Of 161,392 deaths ONLY 6% / 9,683 ARE DIRECTLY CAUSED BY COVID.

This site may earn a commission from merchant affiliate links, including eBay, Amazon, and others.

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
NOTHING TO SEE HERE FOLKS, PLEASE DISPERSE!!! Just a completely healthy doctor DYING 2 weeks after getting the vaccine. Completely NORMAL!!! /s (archive.vn)

A ‘healthy’ doctor died two weeks after getting a COVID-19 vaccine; CDC is investigating why

JAN 07, 2021

A 56-year-old doctor in South Florida died this week, two weeks after getting a first dose of the COVID-19 vaccine.

Two weeks after getting a first dose of a Pfizer COVID-19 vaccine, a 56-year-old doctor in South Florida died this week, possibly the nation’s first death linked to the vaccine.
Health officials from Florida and the Centers for Disease Control and Prevention are investigating what role, if any, the vaccine played in the death of Dr. Gregory Michael, a Miami-Beach obstetrician who, his family says, was in otherwise good health.
Michael received his first dose of Pfizer’s COVID-19 vaccine on Dec. 18 at Mount Sinai Medical Center, according to a Facebook post from his wife, Heidi Neckelmann.
Three days later, small spots began to appear on his feet and hands and he went to the emergency room at Mount Sinai, where he has worked in private practice for 15 years, according to his personal website.

e51136d770f97438235ddb8babcd41fc294d8e71.jpg
 

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
here's a hot one that needs to be explored.
download the CDC document and read for yourself on page 42
https://www.fda.gov/media/134922/download

if the virus is missing and has never been isolated, has never been proved to exist, what are they putting in the COVID vaccine? That’s a question that should be answered by law-enforcement agencies raiding many facilities and seizing materials and finding honest scientists who will discover what is really in the COVID vaccine brews. do you want to take the shot in the arm?

COVID: The Virus That Isn’t There: The Root Fraud Exposed

By Jon Rappoport October 10, 2020

The Smoking Gun: Where is the coronavirus? The CDC says it isn’t available.

The CDC document is titled, “CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” It is dated July 13, 2020.
https://www.fda.gov/media/134922/download

Buried deep in the document, on page 42, in a section titled, “Performance Characteristics,” we have this: “Since no quantified virus isolates of the 2019-nCoV are currently available, assays [diagnostic tests] designed for detection of the 2019-nCoV RNA were tested with characterized stocks of in vitro transcribed full length RNA…”

The key phrase there is: “Since no quantified virus isolates of the 2019-nCoV are currently available…”

Every object that exists can be quantified, which is to say, measured. The use of the term “quantified” in that phrase means: the CDC has no measurable amount of the virus, because it is unavailable. THE CDC HAS NO VIRUS.

A further tip-off is the use of the word ‘isolates.” This means NO ISOLATED VIRUS IS AVAILABLE.
Another way to put it: NO ONE HAS AN ISOLATED SPECIMEN OF THE COVID-19 VIRUS.

NO ONE HAS ISOLATED THE COVID-19 VIRUS.
THEREFORE, NO ONE HAS PROVED THAT IT EXISTS.

As if this were not enough of a revelation to shock the world, the CDC goes on to say they are presenting a diagnostic PCR test to detect the virus-that-hasn’t-been-isolated…and the test is looking for RNA which is PRESUMED to come from the virus that hasn’t been proved to exist.

And using this test, the CDC and every other public health agency in the world are counting COVID cases and deaths…and governments have instituted lockdowns and economic devastation using those case and death numbers as justification.
 

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
They Fought HCQ So Hard Because it possibly Treats HIV at 1/80th - 1/100th of the Cost of Other Antiretrovirals and Likely Had Few to No Side Effects. Trump Ripped the Clothes Right Off the Pharma Emperor

please note this is a work in progress ..

HCQ TREATS HIV

sauce:

Mechanism of HIV Reverse Transcriptase Inhibition by Zinc: *Formation of a Highly Stable Enzyme-(Primer-Template) Compex with Profoundly Diminished Catalytic Activity
Several physiologically relevant cations including Ca2+, Mn2+, and Zn2+ have been shown to inhibit HIV reverse transcriptase (RT), presumably by competitively displacing one or more Mg2+ ions bound to RT....... Essentially, the presence of Zn2+ promotes the formation of a highly stable slowly progressing RT-(primer-template) complex....In conclusion, Zn2+ inhibits HIV-RT synthesis not by directly stopping catalysis, but by forming a highly stable complex that has very slow incorporation kinetics. The RT-Zn2+-(primer-template) complex can be thought of as a “dead-end complex” since it ties up RT- potentially for hours, in a complex that is from a kinetic perspective, minimally productive.

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine
We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes
HCQ inhibited HIV-1 replication (> 75%), as measured by reverse transcriptase activity, in the primary T cells and monocytes as well as the T cell and monocytic cell lines. HCQ itself had no anti-reverse transcriptase activity and was not toxic to the cells at concentrations inhibitory to viral replication. Intracytoplasmic staining with an anti-p24 antibody, 24 h after infection, revealed the presence of intracytoplasmic virus, suggesting that the drug does not block viral entry. The production of steady-state HIV-1 mRNA was not affected by HCQ in that comparable levels of HIV-1 mRNA could be detected by Northern blot analysis and by in situ hybridization in both the HCQ-treated and untreated cells. However, HCQ does appear to affect production of infectious HIV-1 virions because viral isolates from HCQ-treated cells could not infect target CEM cells. These data suggest that HCQ may be useful adjunctive therapy in the treatment of HIV-1 infection.

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1
Hydroxychloroquine (HCQ), an antimalarial agent used to treat patients with autoimmune diseases, has been shown to suppress human immunodeficiency virus type 1 (HIV-1) replication in vitro in T cells and monocytes by inhibiting posttranscriptional modification of the virus. These in vitro observations have been expanded into an in vivo study of HCQ as a potential anti-HIV-1 agent in HIV-1-infected patients. A randomized, double-blind, placebo-controlled clinical trial was conducted in 40 asymptomatic HIV-1-infected patients who had CD4+ counts between 200 and 500 cells/mm3. Patients were randomly assigned to receive either HCQ 800 mg/d or placebo for 8 weeks. Virologic and immunologic parameters, including HIV-1 ribonucleic acid (RNA) via use of polymerase chain reaction, viral culture, antigen and mitogen responses, and proinflammatory cytokine levels were measured at the beginning and end of the study......HCQ thus may be useful in the treatment of patients with HIV-1 infection.

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
HCQ reduces lipopolysaccharide/TLR-mediated immune activation; this compound could be a useful immunomodulant in HIV-infected patients

Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity
Chloroquine and its analog hydroxychloroquine are two inexpensive agents that are widely used for the treatment of malaria and have been shown to achieve some level of anti-HIV activity. The exact mechanism of chloroquine and hydroxychloroquine's anti-HIV activity has not yet been discerned but may be related to effects on HIV's surface envelope glycoprotein 120. If found efficacious, both drugs would offer significant advantages to current therapy including a unique mechanism of action, lack of cross-resistance with other antiretrovirals, and low cost.

The anti-HIV-1 activity of chloroquin
Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) are endowed with a broad anti-HIV-1 activity inhibiting X4, R5, and X4/R5 stains in lymphocytic and monocytic cells. Interestingly, CQ is capable of inhibiting HIV-1 replication at concentrations within the range reported in plasma of individuals chronically treated with doses of the drug which have well-known and limited toxicity. These effects have been confirmed in vivo in two clinical trials. The principal mechanism of HIV-1 inhibition by CQ seems to be an effect on gp120 on a post-transcriptional level. Because CQ and HCQ appear to have a novel site of action (i.e. post-transcriptional inhibition of gp120), these drugs may be particularly useful in combination with other anti-retroviral agents (e.g. ZDV, ddI and HU)

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1
Hydroxychloroquine (HCQ), an antimalarial agent used to treat patients with autoimmune diseases, has been shown to suppress human immunodeficiency virus type 1 (HIV-1) replication in T cells and monocytes in vitro by inhibiting posttranscriptional modification of the virus. An initial randomized, placebo-controlled clinical trial conducted in 38 asymptomatic HIV-1-infected patients who had CD4+ counts between 200 and 500 cells/mm3 demonstrated that the amount of recoverable virus declined significantly in the HCQ group compared with the placebo group over the 8-week study period...Thus HCQ may be potentially useful in the treatment of patients with HIV-1 infection.
 
Last edited:

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
counter point for post #446 pointing out, if no one is able to obtain a sample of SARS CoV-2 complete genome. let me know if anyone has been able to provide an isolated sample of C19 virus complete with detailed notes allowing another lab/researchers to analysis/duplicate.

lab should be able to culture and isolate from an infected patient. then why are there no samples of SARS CoV-2 complete genome available to researchers, say trying to develop a vaccine for SARS CoV-2. which brings up question, how do you know if said vaccine works?

NCBI SARS-CoV-2 Resources
https://www.ncbi.nlm.nih.gov/sars-cov-2/
 

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
Covid has not been scientifically proven to exist. We are being lied to.

Dr, Tom Cowan explains scientifically why covid has not been proven to exist. Well worth the watch to understand how things "work" in the medical/science fields concerning virology.

 

_CY_

Sharpshooter
Supporting Member
Special Hen Supporter
Joined
May 11, 2009
Messages
33,848
Reaction score
6,619
Location
tulsa
American Journal of Medicine as of Jan 2021 now recommending HCQ !!! OUTRAGEOUS!

This is real. You can download it here:
https://www.sciencedirect.com/journal/the-american-journal-of-medicine/vol/134/issue/1

It's the article called "Pathophysiological Basis and Rationale for EarlyOutpatient Treatment of SARS-CoV-2 (COVID-19)Infection"

"Hydroxychloroquine (HCQ) is an antimalarial/anti-inflam-matory drug that impairs endosomal transfer of virionswithin human cells. HCQ is also a zinc ionophore that conveys zinc intracellularly to block the SARS-CoV-2RNA-dependent RNA polymerase, which is the coreenzyme of the virus replication. The currently completedretrospective studies and randomized trials have generallyshown these findings: 1) when started late in the hospitalcourse and for short durations of time, antimalarials appearto be ineffective, 2) when started earlier in the hospitalcourse, for progressively longer durations and in outpa-tients, antimalarials may reduce the progression of disease,prevent hospitalization, and are associated with reducedmortality"

https://www.amjmed.com/action/showPdf?pii=S0002-9343(20)30673-2

https://web.archive.org/web/2021012....com/action/showPdf?pii=S0002-9343(20)30673-2

Source and archive

JtEjmaMe.jpeg
 

Latest posts

Top Bottom